SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
External view of the U.S. Capitol building
Government
Senate Confirms Makary as FDA Chief as Trump’s Health Nominees Move Forward
Marty Makary earlier this month distanced himself from the recent shake-ups at the FDA, including the cancellation of its vaccines advisory committee meeting and the steep layoffs at the agency.
March 26, 2025
 · 
2 min read
 · 
Tristan Manalac
Podcast
Trump’s Pharma Tariffs, Monarez for CDC, Novo’s New Obesity Play, More
President Donald Trump continues to warn of tariffs on the pharmaceutical industry; Susan Monarez replaces Dave Weldon as CDC director nominee; Novo Nordisk joins the triple-G race; Alnylam wins approval for Amvuttra in ATTR-CM; and Cassava Sciences ends development of simufilam in Alzheimer’s.
March 26, 2025
 · 
1 min read
 · 
Heather McKenzie
A look into the future. Concept. stock photo
GLP-1
BioSpace Presents the World Atlas of GLP-1s
Eli Lilly and Novo Nordisk are in a global battle for dominance in the weight loss space. BioSpace takes a look at the territory covered and what’s to come.
March 26, 2025
 · 
2 min read
 · 
Annalee Armstrong
Contemporary art collage. Person climbs a pile of colorful capsules, symbolizing struggle and progress in surreal pharmaceutical world. Flag marks goal at top. stock photo
Manufacturing
GLP-1 Injectables Will Soon Be Joined by Orals. Is the Industry Ready to Scale?
With crucial lessons learned from the manufacturing shortages of injectable GLP-1s, experts say securing adequate supply of the upcoming oral options will be the sector’s next great challenge.
March 26, 2025
 · 
6 min read
 · 
Ben Hargreaves
Receiving dividends among investors. Art collage.
Biosimilars
Humira Biosimilars Gain Ground as Doctors Adjust and New Therapies Rise
AbbVie’s Humira was the top-selling drug in the world for many years. Now, its sales are eroding as doctors switch to biosimilars and new options enter the market.
March 26, 2025
 · 
6 min read
 · 
Annalee Armstrong
Lost at sea strategic crisis and strategy trouble concept as a target floating aimlessly in an ocean of confused blue darts as a business metaphor for economic or corporate plan despair as a 3D illustration.
Alzheimer’s disease
Cassava Finally Ends Alzheimer’s Program for Embattled Simufilam
After years of controversy and allegations of doctored data, Cassava is moving on from Alzheimer’s.
March 25, 2025
 · 
1 min read
 · 
Annalee Armstrong
Illustration of young woman standing in front of exit door
Layoffs
Alector Cuts Staff Again, This Time Laying Off 13% of Workforce
As part of cost-cutting efforts, Alector is letting go of about 25 people as it focuses on advancing its preclinical and research pipeline. Alector is also continuing clinical-stage work on programs for frontotemporal dementia and Alzheimer’s disease.
March 25, 2025
 · 
2 min read
 · 
Angela Gabriel
Businessmen working together installing gears in human head, business initiative, mindset improvement concept
Vaccines
GSK Builds on Real-World Experiment to Study Shingrix’s Impact on Dementia
The British pharmaceutical giant is working with the U.K. Dementia Research Institute to exploit a “natural randomization” experiment to determine whether 65- and 66-year-olds who received GSK’s shingles vaccine Shingrix have reduced dementia risk.
March 25, 2025
 · 
1 min read
 · 
Dan Samorodnitsky
Illustration showing hands holding arrow that goes up and down a few times and ends up in upward direction
Compensation
Average Life Sciences Salaries Up 9% in 2024, but Bonuses and Equity Values Drop: BioSpace Report
The 9% average salary increase from 2023 to 2024 was the largest for life sciences professionals since 2021. Several factors could be behind the spike, including companies providing higher pay because bonuses and stock compensation went down.
March 25, 2025
 · 
3 min read
 · 
Angela Gabriel
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS